Thus, PvUIS4 staining, in combination with the characteristic small size of the parasite, is currently the only hypnozoite-specific morphological marker available

Thus, PvUIS4 staining, in combination with the characteristic small size of the parasite, is currently the only hypnozoite-specific morphological marker available. Results Here, the generation and validation of a recombinant monoclonal antibody against PvUIS4 (-rUIS4 mAb) is described. and IgK expression vectors. These expression plasmids were co-transfected into HEK293 cells and mature IgG was purified from culture supernatants. It is shown that the -rUIS4 mAb binds to its target with high affinity. It reliably stains the schizont PVM and the hypnozoite-specific PVM prominence, enabling the visual differentiation of hypnozoites from replicating liver stages by immunofluorescence assays in different in vitro settings, as well as in liver sections from infected liver-chimeric mice. The antibody functions reliably against all four parasite EIPA hydrochloride isolates tested and will be an important tool in the identification of the elusive hypnozoite. Conclusions The -rUIS4 mAb is a versatile tool for distinguishing replicating liver stages from dormant hypnozoites, making it a valuable resource that can be deployed throughout laboratories worldwide. Keywords: is the predominant cause EIPA hydrochloride of malaria in Africa [1], has the widest geographical distribution and is estimated to be responsible for nearly half the cases of malaria outside of sub-Saharan Africa, leading to 50,000C100,000 deaths annually [2]. Infection is initiated with the bite of an infected female mosquito, which injects tens to hundreds of motile sporozoites into the skin [3]. The sporozoites traverse skin and endothelial cells to gain access to the blood circulation through which they are transported to the liver [4]. Once in the liver, sporozoites are sequestered in the sinusoids and enter the liver parenchyma where they infect hepatocytes which marks the beginning of the asymptomatic liver stage infection [5]. Approximately 7C9?days after sporozoite infection, tens of thousands of exo-erythrocytic merozoites are released from each infected hepatocyte and enter the bloodstream to infect human red blood cells. The following erythrocytic stage of infection, in which the number of parasites increases exponentially as well as ensures transmission to the mosquito vector, is responsible for all the clinical symptoms associated with malaria [6]. The pre-erythrocytic stage is a favourable target for intervention strategies, as preventing the release of exoerythrocytic merozoites from the liver would stop the disease before the onset of clinical symptoms and would prevent transmission. Also, the liver stages of do not develop drug resistance like it has been reported for the blood stages, likely due to a lower burden of liver parasites (10C102) as compared to blood stage parasites (109C1013) [7]. Importantly, it is at the liver stage where differs greatly from forms dormant liver stages, termed hypnozoites, that create a reservoir of non-replicating, persistent parasites. These re-activate periodically and lead to new symptomatic blood stage infections, termed relapses, without new exposure to parasite-infected mosquitoes [8]. Remarkably, it has been reported that 80C90% of infections are due to relapses and not to newly acquired infections [9]. Primaquine is the only drug that has been approved for preventing relapse of EIPA hydrochloride infection. However, incompatibility with glucose-6-phosphate-dehydrogenase (G6PD) deficiency, treatment failures associated with decreased cytochrome P450-2D6 activity, and primaquines short half-life and long dosage regimens combine to diminish its usefulness in mass elimination campaigns [10, 11]. Thus, the potential for long-term latency and lack of a safe, efficacious, single-dose drug effective against hypnozoites threatens the World Health Organization (WHO) goals of reducing malaria incidence and mortality rates by 90% and eliminating the disease from 35 endemic countries in the next 15?years [2]. The development of new research technologies, including in vitro infection of primary hepatocytes [12] and in vivo liver stage infections of liver-chimeric mice [13] has bolstered efforts to generate improved hypnozonticidal anti-malarials and liver stage-targeted vaccines. However, a critical point in both the in vitro and in vivo liver stage models of is distinguishing between dormant hypnozoites and replicating liver stages. It was shown previously that hypnozoites can readily be distinguished from replicating liver stages by staining with an antibody against PvUIS4 PRKMK6 (Upregulated in Infectious Sporozoites 4) [13]. UIS4 localizes to the parasitophorous vacuole membrane (PVM), a prominent feature of all liver stages which separates the parasite from the host cell.